Page 5 - ப்ராடக்ட் சோதனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ப்ராடக்ட் சோதனை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ப்ராடக்ட் சோதனை Today - Breaking & Trending Today

Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of Directors

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of Directors
Reata Pharmaceuticals, Inc.April 15, 2021 GMT
PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointments of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021.
“We are excited to welcome Ms. Ruff and Ms. Oliger to Reata’s board,” said Warren Huff, Reata’s Chief Executive Officer and President. “They join at a critical point in Reata’s development having just submitted our first New Drug Application for bardoxolone methyl (“bardoxolone”) for the treatment of chronic kidney disease caused by Alport syndrome. Both Ms. Ruff and Ms. Oliger bring a wealth of experience that will ....

United Kingdom , United States , Andres Lorente , Christyj Oliger , Manmeet Soni , University Of Loughborough , Sarepta Therapeutics Inc , Member Of The Royal Society Chemistry , Karyopharm Therapeutics Inc , University Of Leicester , Regulatory Affairs , Stoke Therapeutics Inc , Genentech Inc , Exchange Commission , University Of California At Santa Barbara , Reata Pharmaceuticals Inc , Amgen Inc , Plough Corporation , Abbott Laboratories , Roche Holding , Shamim Ruff , Warren Huff , Chief Executive Officer , New Drug Application , Schering Plough Corporation , Senior Vice President ,

Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Claritas Announces Letter of Intent to Acquire Exclusive Worldwide Rights to Develop R-107 for PAH
Claritas Pharmaceuticals, Inc.April 14, 2021 GMT
SAN FRANCISCO and TORONTO, April 14, 2021 (GLOBE NEWSWIRE) Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced that it has entered into a binding Letter of Intent (the “LOI”) with Salzman Group, Inc. (a Delaware corporation), Salzman Group, Ltd. (an Israeli corporation), and Salzman Group Pty. Ltd. (an Australian corporation), (collectively, the “Salzman Group”), under which Salzman Group will grant to Claritas an exclusive, worldwide license to develop and commercialize R-107 for the treatment of pulmonary arterial hypertension (“PAH”). The Company expects that definitive agreements will be executed by May 15, 2021. Closing of the transaction is sub ....

South Australia , United States , South Korea , San Francisco , Salvador Moncada , Robert Farrell , Adrianh Chester , Magdih Yacoub , Company Or Claritas , Claritas Pharmaceuticals , View Research , Salzman Group Inc , Salzman Group Ltd , Salzman Group , Claritas Pharmaceuticals Inc , Venture Exchange , Salzman Group Pty , Regulation Services Provider , Clarita Development Plan , Nitric Oxide Releasing , License Agreement , Will Develop , Nitric Oxide Therapy , Both Viral Infections , Clarita President , Nitric Oxide ,

Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in .
Oxurion NVApril 12, 2021 GMT
Leuven, Belgium, Boston, MA, US, 12 April 2021 – 7.30 AM CET – ONCURIOUS NV, a Belgium-based biotech company focused on developing innovative oncology treatments, today announces that encouraging data from a Phase 1 dose escalation study of TB-403 in pediatric subjects with relapsed or refractory medulloblastoma (MB), was presented at the annual meeting of the American Association for Cancer Research (AACR).
The data was presented by Dr. Giselle Sholler, Director, Isabella Santos Foundation Solid and Rare Tumor Program, Chair at Beat Childhood Cancer Research Consortium, and Professor, Paediatric Oncology at the Levine Children’s Hospital in Charlotte, NC. ....

United States , Region Flamande , Elisabeth Stes , Rakesh Jain , Peter Carmeliet , Wouter Piepers , Giselle Sholler , Sylvie Berrebi Frazer Hall , Citigate Dewe Rogerson , Isabella Santos Foundation Solid , Hasselt University , Ghent University , Rare Tumor Program , Beat Childhood Cancer Research Consortium , American Association For Cancer Research , Atrium Health Levine Children Hospital , Corporate Communications , University Of Antwerp , American Association , Cancer Research , Paediatric Oncology , Levine Children , Ewing Sarcoma , Massachusetts General Hospital , Atrium Health Levine Children , Prof Rakesh Jain ,

Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Valneva Completes Recruitment for Pivotal Phase 3 Trial of Chikungunya Vaccine Candidate and .
VALNEVAApril 12, 2021 GMT
Saint-Herblain (France), April 12, 2021 – Valneva SE (“Valneva” or “the Company”), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced that it has completed recruitment for the pivotal Phase 3 trial, VLA1553-301, of its single-shot chikungunya vaccine candidate, VLA1553. The sponsor of the first chikungunya vaccine Biologics License Application (BLA) to be approved in the U.S. will be eligible to receive a Priority Review Voucher (PRV) 1. ....

Juan Carlos Jaramillo , Instituto Butantan , European Medicines Agency , Drug Administration , Government Public Affairs , Coalition For Epidemic Preparedness Innovations , Investor Relations Corporate Communications , Biologics License Application , Priority Review Voucher , Carlos Jaramillo , Chief Medical Officer , Fast Track , Middle Income Countries , Epidemic Preparedness Innovations , Media Contacts , Public Health , Products And Services , Drug Approvals , Coronavirus Pandemic , Product Approvals , Product Testing , Intellectual Property , Globe Newswire , Pharmaceutical Manufacturing , Health Care Industry , Lung Disease ,

ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for .
ORIC PharmaceuticalsApril 12, 2021 GMT
SOUTH SAN FRANCISCO and SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, presented four preclinical poster presentations at the 2021 American Association for Cancer Research (AACR) virtual annual meeting.
ORIC-101: Glucocorticoid Receptor (GR) Antagonist
ORIC-101 is a potent and selective GR antagonist, with two distinct mechanisms of action being evaluated in two Phase 1b trials in combination with: (1) Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors and (2) Xtandi (enzalutamide) in metastatic prostate cancer. ....

United States , South San Francisco , San Diego , Dominic Piscitelli , Exchange Commission , American Association For Cancer Research , Securities Exchange , Pharmaceuticals Inc , Cancer Research , Glucocorticoid Receptor , Securities Act , Securities Exchange Act , Chief Financial , Products And Services , Government Regulations , Coronavirus Pandemic , Product Testing , Globe Newswire , Pharmaceutical Manufacturing , Health Care Industry , Women X27s Health , Lung Disease , New Products And Services , Medical Research , Drug Trials , Covid 19 Pandemic ,